Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.
The next frontier in medicine: drugs designed by artificial intelligence
More of Today's Solutions
Kenya unlocks $160 million to protect the Maasai Mara and Tsavo ecosystems
BY THE OPTIMIST DAILY EDITORIAL TEAM Kenya committed $160 million over ten years to protect 173,000 square kilometers (roughly 67,000 square miles, or 17.3 ...
Read MoreWill vinegar actually keep bugs out this fall? Pest experts explain what works
BY THE OPTIMIST DAILY EDITORIAL TEAM As temperatures drop, bugs start looking for the same thing you do: somewhere warmer. If you've been reaching ...
Read MoreStronger concrete, cleaner landfills—how scrap carpet fibers are reinventing ...
BY THE OPTIMIST DAILY EDITORIAL TEAM Concrete is the foundation of modern civilization, but its notorious tendency to crack isn’t just a construction headache—it’s ...
Read MoreHow sheep are powering the solar boom in a win for sustainability and agricul...
BY THE OPTIMIST DAILY EDITORIAL TEAM On a sprawling solar farm in rural Texas, thousands of sheep are hard at work. Beneath rows of ...
Read More
